PER® Winter Lung Cancer Conference | Conference

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC

February 3rd 2024

Benjamin Levy, MD, discusses the mechanism of action of antibody-drug conjugates in patients with non–small cell lung cancer.

Dr Leal on the Development of DLL3-Targeted Agents in SCLC

February 3rd 2024

Ticiana Leal, MD, discusses the variety of DLL3-targeted agents in development for patients with small cell lung cancer and neuroendocrine tumors.

Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC

February 3rd 2024

Bruna Pellini, MD, discusses the importance of developing circulating tumor DNA assays with increased sensitivity.

Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC

February 3rd 2024

Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

Immunotherapy Must Become More Precise and Personalized in Lung Cancer

February 7th 2023

To continue making progress in lung cancer treatment, investigators must keep pushing the science in new directions even as immunotherapy becomes more available in earlier lines.

Rising Standards in Regulatory Decisions Highlight Challenges in Drug Development in Lung Cancer

February 6th 2023

If the FDA’s Oncologic Drugs Advisory Committee meeting held on February 10, 2022, was any indication, the days of applying foreign single country or region data to support regulatory approval are gone; instead, regulatory decisions are headed toward the need for regional consistency through multiregional clinical trials, which could help the United States overcome the persistent underrepresentation of racial and ethnic minorities in drug development.

PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC

February 6th 2023

As more agents are evaluated either in addition to or following PD-1/PD-L1 inhibitors, more information may be learned about how best to leverage alternate biomarkers, according to Marina C. Garassino, MD.

Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC

February 6th 2023

FDA approvals in recent years have started to carve out a role for immunotherapy in the frontline treatment of patients with small cell lung cancer.

Efforts to Effectively Target Rare Oncogenes Propel Progress in Lung Cancer

February 10th 2022

With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.

Dr. Bazhenova on Questions With Trastuzumab Deruxtecan in HER2-Mutated Lung Cancer

February 9th 2022

Lyudmila A. Bazhenova, MD, discusses future research questions with fam-trastuzumab deruxtecan-nxki in HER2-mutated lung cancer.

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

February 8th 2022

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC

February 8th 2022

Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.

Dr. Hales on the Role of Multidisciplinary Care in Locally Advanced Lung Cancer

February 7th 2022

Russell Kenneth Hales, MD, discusses the role of multidisciplinary care in locally advanced lung cancer.

Dr. Levy on Potential Methods to Optimize Molecular Testing in Lung Cancer

February 7th 2022

Benjamin Philip Levy, MD, discusses potential methods to optimize molecular testing in lung cancer.

ADCs Showcase Impressive Activity, Second-Line Combos Seek to Raise the Bar in Quest to Target HER2+ NSCLC

February 7th 2022

Antibody-drug conjugates appear to have the most activity in those with non–small cell lung cancer and HER2 expression.

Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance

February 7th 2022

Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.

Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC

February 7th 2022

Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.

Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC

February 7th 2022

Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.

Immunotherapy Advances Drive Progress in Lung Cancer Treatment

February 5th 2022

In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.